Adaptive Biotechnologies Corporation
ADPT Healthcare Diagnostics & Research
Adaptive Biotechnologies Corporation’s revenue for fiscal 2025 (year ended December 2025) was $277.0 million, up 54.8% from fiscal 2024. In the quarter to June 2026, revenue grew 21.5%, EPS fell 47.1% and free cash flow grew 42.0%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
Follow ADPT
Adaptive Biotechnologies Corporation (ADPT) EV/Sales
As of 16 October 2026, Adaptive Biotechnologies Corporation (ADPT) trades at a EV/Sales of 12.4×. Over the past ten years it has ranged from −0.3× (September 2019) to 86.6× (December 2020); the current reading is higher than 65% of that period. That is above the Diagnostics & Research industry median of 5.5× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 8.9× | 80.52% |
| FY2024 | 4.9× | 49.10% |
| FY2023 | 3.3× | (27.13%) |
| FY2022 | 4.5× | (81.10%) |
| FY2021 | 23.9× | (67.20%) |
| FY2020 | 72.9× | 305.70% |
| FY2019 | 18.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 11.1× | 51.88% |
| Mar 2026 | 7.3× | (17.57%) |
| Dec 2025 | 8.9× | (1.98%) |
| Sep 2025 | 9.0× | 3.56% |
| 28 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| RDNT RadNet, Inc. compare | 2.6× |
| NEO NeoGenomics, Inc. compare | 3.4× |
| WGS GeneDx Holdings Corp. compare | 4.1× |
| VCYT Veracyte, Inc. compare | 5.3× |
| SHC Sotera Health Company compare | 5.7× |
| CDNA CareDx, Inc. compare | 6.4× |
| BLLN BillionToOne, Inc. compare | 10.3× |
| ADPT Adaptive Biotechnologies Corporation | 12.4× |
| GRAL GRAIL, Inc. compare | 25.5× |
| Diagnostics & Research industry median | 5.5× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)